Galapagos Signs Research Agreement with UCL
News May 21, 2008
Galapagos NV has announced that is has signed a drug discovery research agreement with UCL (University College London). Galapagos' BioFocus DPI service division will perform medicinal chemistry services for a UCL research project.
It is also intended that BioFocus DPI will offer UCL ADME screening facilities during the appropriate stages of the work. Total contract value for Galapagos is expected to reach more than €1.8 million over the course of the two-year agreement.
UCL has an ongoing drug discovery program for the treatment of vascular collapse during sepsis (collapsing of blood vessels due to systemic infection by a pathogen).
BioFocus DPI will provide medicinal chemistry services to progress UCL's lead series through to pre-clinical testing.
In addition UCL will also have the opportunity to utilize BioFocus DPI ADME screening services and will receive access to a selection of compounds in BioFocus DPI's SoftFocus collection to facilitate the identification of new chemical starting points for this drug discovery program.
"We are pleased to add UCL to BioFocus DPI's considerable list of academic partners," said Onno van de Stolpe, CEO of Galapagos. "BioFocus DPI's leading medicinal chemistry and ADME expertise, such as the newly launched ADME/PK Laboratory, give us a strong edge in winning highly competitive deals."
AIDS Vaccine Design: New Data Offers Important InsightNews
New data published in Immunity further illuminate how some human beings generate powerful, HIV-blocking antibodies. The results offer important insight into a potential AIDS vaccine design.READ MORE
Elpis BioMed Closes Funding Round to Commercialise Novel Technology Platform for Generating Human Cell TypesNews
New Cambridge spin-out company commercialises disruptive technology that enables rapid generation of pure and consistent batches of human cell types. Geographically diversified, top-tier investor team includes key industry leaders to support early company development.READ MORE